Takeda in schizophrenia research alliance with Envoy Thera

11 October 2010

Japan’s largest drugmaker Takeda Pharmaceutical (TSE:4502) has formed a three-year research alliance Envoy Therapeutics, a recently-formed US drug discovery company, aimed at discovering drugs for schizophrenia that will have greater efficacy and safety compared to current therapies.

Under the terms of the agreement, Osaka-based Takeda will make a $3 million upfront payment as well as providing $2.25 million per year in research funding and fees. In addition, Envoy will receive potential progress-dependent milestone payments and royalties should one or more compounds advance to clinical development and commercialization.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK